Observational study of relapsed diffuse large B-cell lymphoma presenting as indolent lymphoma
Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting as Indolent Lymphoma
This study looks at how diffuse large B-cell lymphoma can come back as a slower-growing type of lymphoma to see what signs and treatments might help patients better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Azienda USL Reggio Emilia - IRCCS Government |
| Locations | 1 site (Reggio Emilia) |
| Trial ID | NCT06822829 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the epidemiological and clinical characteristics of diffuse large B-cell lymphoma (DLBCL) that relapses as indolent lymphoma. It focuses on identifying diagnostic and imaging features associated with such relapses and evaluating the response to selected therapies. The study will analyze data from patients diagnosed between 2010 and 2020, gathering clinical and laboratory information related to both the initial diagnosis and the relapse. The goal is to better understand this rare phenomenon and improve treatment strategies.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a previous diagnosis of diffuse large B-cell lymphoma and documented relapses as indolent lymphoma.
Not a fit: Patients without a prior diagnosis of diffuse large B-cell lymphoma or those who do not have documented relapses as indolent lymphoma may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the characteristics and treatment of relapsed DLBCL presenting as indolent lymphoma, potentially leading to improved patient outcomes.
How similar studies have performed: While there is limited literature on this specific phenomenon, the study aims to fill a gap in knowledge, suggesting that similar studies have not extensively explored this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or older at the time of diagnosis. * Previous diagnosis of diffuse large B-cell lymphoma with/without a discordant component of indolent B-cell lymphoma, or previous diagnosis of diffuse large B-cell lymphoma transformed from indolent B-cell lymphoma. * First-line treatment for diffuse large B-cell lymphoma. * Histologically documented relapse of indolent B-cell lymphoma, diagnosed between 2010 and 2020. * Availability of the histological report of the relapse. * Availability of clinical and laboratory data related to both the initial diagnosis and relapse. * Availability of follow-up data. * Consent to participate in the study and signing of the specific informed consent form (for living and/or contactable patients). Exclusion Criteria: \- None
Where this trial is running
Reggio Emilia
- Azienda USL IRCCS di Reggio Emilia — Reggio Emilia, Italy (Recruiting)
Study contacts
- Principal investigator: Maria Elena Nizzoli, MD — Azienda USL - IRCCS di Reggio Emilia
- Study coordinator: Attilio Gennaro, Clinical Research Coordinator
- Email: attilio.gennaro@ausl.re.it
- Phone: +39 0522 295175
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.